CIRCA Scientific Announces Successful First Procedures with CrossWise™ RF Transseptal Access System
The CrossWise system delivers RF energy directly to the tip of a shapeable, radiopaque cannula, enabling precise navigation and controlled crossing during procedures requiring left heart access, such as atrial fibrillation ablations, left atrial appendage occlusions, and mitral valve interventions. Its zero-exchange design allows clinicians to maintain guidewire accessibility throughout, enhancing procedural efficiency by eliminating additional steps and reducing the need for extra consumables.
"The introduction of CrossWise represents a meaningful advancement in transseptal access," said
Dr
CrossWise is the first commercial release of a new product under CIRCA Scientific's CardioCentric™ strategy to expand its product portfolio with advanced solutions for complex medical interventions in Cardiac Electrophysiology and Interventional Cardiology.
About Circa Scientific:
CIRCA Scientific is dedicated to empowering physicians with innovative technologies that offer unprecedented access and control for complex medical interventions. Guided by a CardioCentric™ approach, we are committed to enhancing procedural success and advancing patient care. For more information on CIRCA Scientific and its portfolio of cardiac solutions, visit www.circascientific.com.
© CIRCA Scientific, Inc., 2025. All rights reserved. CrossWise, CardioCentric, CIRCA Scientific, and the CIRCA Scientific logo are trademarks of CIRCA Scientific, Inc. Patents: www.circascientific.com/patents. CAUTION: US law restricts this device to sale by or on the order of a physician. Before use, consult instructions for use supplied with this device for indications, contraindications, side effects, warnings, and precautions.
View original content to download multimedia:https://www.prnewswire.com/news-releases/circa-scientific-announces-successful-first-procedures-with-crosswise-rf-transseptal-access-system-302348716.html
SOURCE CIRCA Scientific, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Via Motif Named 2026 Top Handcrafted Hospitality Accessories Provider by Hospitality Business Review
- Fingercheck Earns 25 G2 Fall 2026 Badges on Strength of Customer Satisfaction
- Bold Therapeutics Reaches Enrollment Midpoint in Randomized Phase 2 Trial of BOLD-100 in Second-Line Metastatic Colorectal Cancer
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!





Tweet
Share